Oral administration of bruton’s tyrosine kinase inhibitors impairs GPVI-mediated platelet function

American Journal of Physiology - Cell Physiology

Volumn 310, Issue 5, 2016, Pages C373-C380

  Rigg, Rachel A ^a   Aslan, Joseph E ^a,b   Healy, Laura D ^b   Wallisch, Michael ^a   Thierheimer, Marisa L D ^a   Loren, Cassandra P ^a   Pang, Jiaqing ^a   Hinds, Monica T ^a   Gruber, András ^a,c   McCarty, Owen J T ^a,b,c  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bruton s tyrosine kinase; Glycoprotein VI; Ibrutinib; Platelets

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; BTKI 43607; BTKI 43761; FIBRINOGEN; GLYCOPROTEIN VI; IBRUTINIB; PADGEM PROTEIN; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; FIBRINOGEN RECEPTOR; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CELL SPREADING; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHEAR FLOW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BABOON; BLEEDING; CHEMICALLY INDUCED; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PAPIO; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84979986145     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00325.2015     Document Type: Article

References (26)

1. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31: 88-94, 2013
2. Aslan JE, Itakura A, Gertz JM, McCarty OJ. Platelet shape change and spreading. Methods Mol Biol 788: 91-100, 2012
3. Aslan JE, Itakura A, Haley KM, Tormoen GW, Loren CP, Baker SM, Pang J, Chernoff J, McCarty OJ. p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear. Arterioscler Thromb Vasc Biol 33: 1544-1551, 2013
4. Aslan JE, Tormoen GW, Loren CP, Pang J, McCarty OJ. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 118: 3129-3136, 2011
5. Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood 102: 3592-3599, 2003
6. Bhatt V, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton’s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy 34: 303-314, 2014
7. Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal 22: 1175-1184, 2010
8. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O’Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125: 2915-2922, 2015
9. Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins JM. Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol 35: 2326-2335, 2015
10. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32-42, 2013
11. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28: 649-657, 2014
12. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 86: 214-221, 2001
13. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117: 6287-6296, 2011
14. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS. Ibrutinib inhibits collagenmediated but not ADP-mediated platelet aggregation. Leukemia 29: 783-787, 2015
15. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sie P, Ysebaert L, Payrastre B. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 124: 3991-3995, 2014
16. Li Z, Delaney MK, O’Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30: 2341-2349, 2010
17. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108: 2596-2603, 2006
18. Lopez-Herrera G, Vargas-Hernandez A, Gonzalez-Serrano ME, Berron-Ruiz L, Rodriguez-Alba JC, Espinosa-Rosales F, Santos-Argumedo L. Bruton’s tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 95: 243-250, 2014
19. Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O’Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol 75: 111-121, 2015
20. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 102: 449-461, 2003
21. Quek LS, Bolen J, Watson SP. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8: 1137-1140, 1998
22. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger AC, Witte ON, Kinet JP. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 271: 822-825, 1996
23. Séverin S, Nash CA, Mori J, Zhao Y, Abram C, Lowell CA, Senis YA, Watson SP. Distinct and overlapping functional roles of Src family kinases in mouse platelets. J Thromb Haemost 10: 1631-1645, 2012
24. Thornber K, McCarty OJ, Watson SP, Pears CJ. Distinct but critical roles for integrin αIIbβ3 in platelet lamellipodia formation on fibrinogen, collagen-related peptide and thrombin. FEBS J 273: 5032-5043, 2006
25. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507-516, 2013
26. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin αIIbβ3 signaling in platelets. J Thromb Haemost 3: 1752-1762, 2005.